Notably, the high-risk group presented overexpression of three cuproptosis biomarkers: CDKN2A, DLD, and DLAT; moreover, tumor tissues of this group have more tumor mutation burden and less immune cell infiltration. The gene discussed is DLD; the disease is neoplasm.